STOCK TITAN

Philips partners with DiA Imaging Analysis to enhance ultrasound with AI-based image quantification

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Royal Philips (NYSE: PHG) announced a strategic partnership with DiA Imaging Analysis to enhance point-of-care ultrasound imaging through AI-powered solutions. This collaboration aims to improve diagnostic confidence and operational efficiency for clinicians, making healthcare more accessible. DiA’s FDA cleared AI technology will automate and enhance image analysis, addressing issues of subjectivity and variability in ultrasound interpretation. Philips will showcase these AI-enabled advancements at the upcoming European Congress of Radiology 2021 virtual event.

Positive
  • Strategic partnership with DiA Imaging enhances Philips' ultrasound imaging solutions.
  • Utilization of AI technology aims to improve diagnostic confidence and operational efficiency.
  • FDA cleared and CE marked applications support clinicians of varied experience levels.
Negative
  • None.

March 2, 2021

Amsterdam, the Netherlands and Be'er Sheva, Israel – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and DiA Imaging Analysis Ltd., a leading provider of AI-powered applications for ultrasound, today announced a strategic partnership* to deliver automated solutions to clinicians at the point-of-care. Philips’ industry leading ultrasound image quality combined with DiA’s AI library of automated solutions will help increase diagnostic confidence, operational efficiency, and access to care for Point-of-Care customers in and out of the hospital.

Philips continues to build suites of intelligent and automated enhancements integrated into Radiology workflows across its portfolio to benefit customers and patients alike. By facilitating the development and integration of AI-enabled applications, Philips aims to enhance its ability to deliver on the Quadruple Aim of better patient outcomes, improved patient and staff experiences and lower cost of care. The integration of AI applications within ultrasound technology can also help lead to improved access to care.

While ultrasound is a cost-efficient diagnostic imaging modality, it currently requires a significant level of operator experience and visual interpretation to use it effectively. In particular, the subjectivity and variability associated with visual interpretation pose a challenge for longitudinal assessments to gauge patient improvement or deterioration. To reduce the variability, improve the efficiency and increase the accuracy of image analysis, DiA Imaging has developed FDA cleared and CE-marked AI-enabled 2D ultrasound applications.

“This partnership with DiA Imaging Analysis reinforces Philips’ commitment to integrating AI partners into the Radiology workflow ecosystem, from the modality, to interpretation, all the way through to results communication,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “Through our strategic partnership with DiA Imaging Analysis, we can deliver unprecedented diagnostic confidence and operational efficiency to point-of-care ultrasound imaging, as well as widen access to high quality and timely care both inside and outside of hospitals.”  

“With superb image quality and ability to operate with smartphones and tablets, Philips Ultrasound devices are widely accepted as the industry’s most advanced solution for point-of-care imaging. As such, it is the ideal platform for deploying AI-enabled solutions that will benefit patients by helping clinicians to make better-informed decisions,” said Hila Goldman Aslan, CEO and Co-Founder, of DiA Imaging Analysis Ltd.

DiA’s AI technology automates the process of manually capturing and visually analyzing ultrasound images. The company’s LVivo Toolbox includes a range of FDA cleared and CE marked automated AI-enabled apps focused on cardiac and abdominal ultrasound analysis to help support clinicians with varying levels of ultrasound experience.

Philips will spotlight its AI-enabled solutions across its imaging portfolio at the upcoming  European Congress of Radiology 2021 virtual event (March 3-7, 2021). For more information on Philips’ new portfolio of diagnostic and interventional solutions, including the new Philips Abdominal Aortic Aneurysm (AAA) Model which seamlessly integrates 3D Ultrasound with innovative software in a single solution, visit the Philips ECR site, and follow @PhilipsLiveFrom for updates throughout the event.

* As part of the partnership, Philips owns a minority interest in DiA Imaging Analysis.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

Edith Schlanger
DiA Imaging Analysis
E-mail: edith@dia-analysis.com

 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

 

About DiA Imaging Analysis Ltd.

DiA Imaging Analysis is a leading provider of AI-powered ultrasound analysis solutions that make the use and analysis of ultrasound images smarter, faster and accessible to all. The company's FDA cleared and CE marked LVivo product line for cardiac and abdominal auto analysis allow clinicians with various levels of ultrasound experience to use and analyze ultrasound images on their ultrasound devices or healthcare IT systems with increased speed, efficiency and accuracy. DiA currently serves thousands of end users worldwide. For additional information, please visit www.dia-analysis.com


Attachments


KONINKLIJKE PHILIPS N.V.

NYSE:PHG

PHG Rankings

PHG Latest News

PHG Stock Data

24.39B
939.94M
7.11%
0.25%
Medical Devices
Healthcare
Link
United States of America
Amsterdam